Sheaff Brock Investment Advisors LLC Sells 3,985 Shares of Gilead Sciences, Inc. (GILD)

Sheaff Brock Investment Advisors LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,200 shares of the biopharmaceutical company’s stock after selling 3,985 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Gilead Sciences were worth $1,854,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares during the period. Legal & General Group Plc boosted its position in shares of Gilead Sciences by 9.3% in the second quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock worth $495,778,000 after buying an additional 596,992 shares during the period. AQR Capital Management LLC boosted its position in shares of Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after buying an additional 1,066,172 shares during the period. Swiss National Bank boosted its position in shares of Gilead Sciences by 2.3% in the second quarter. Swiss National Bank now owns 4,775,524 shares of the biopharmaceutical company’s stock worth $338,012,000 after buying an additional 107,400 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Gilead Sciences by 6.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 4,706,832 shares of the biopharmaceutical company’s stock worth $333,150,000 after buying an additional 302,787 shares during the period. Institutional investors and hedge funds own 74.62% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.85 on Tuesday. The company has a market capitalization of $96,363.46, a P/E ratio of 7.70, a PEG ratio of -1.24 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the business earned $2.75 EPS. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is 23.69%.

Several analysts have recently commented on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 17th. Redburn Partners initiated coverage on Gilead Sciences in a research report on Wednesday, July 26th. They issued a “buy” rating for the company. Finally, BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $84.87.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the transaction, the insider now owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 446,819 shares of company stock worth $36,269,486. Company insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sheaff Brock Investment Advisors LLC Sells 3,985 Shares of Gilead Sciences, Inc. (GILD)” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/sheaff-brock-investment-advisors-llc-sells-3985-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply